|

Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs

RECRUITINGSponsored by Qilu Hospital of Shandong University
Actively Recruiting
SponsorQilu Hospital of Shandong University
Started2025-08-31
Est. completion2026-06-30
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07136701

Summary

The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs). The main questions it aims to answer are: Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions. Participants will: Provide retrospective clinical, pathological, and metabolic data from hospital records. Have survival and recurrence outcomes assessed through follow-up data review.

Eligibility

Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.

Exclusion Criteria:

* Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.

Conditions2

CancerPancreatic Neuroendocine Neoplasms (pNETs)

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.